Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab-assisted peanut oral immunotherapy in adults with peanut allergy
ACTRN12620001203943Phase 4Active, not recruiting
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of omalizumab and peanut oral immunotherapy (UNC Chapel Hill) in peanut allergy, sponsored by St Vincent's Hospital Sydney. Primary endpoint: Maximum tolerated dose of peanut at Week 48. Started Nov 2020; status: active, not recruiting.
02
Drugs
omalizumabpeanut oral immunotherapy (UNC Chapel Hill)
03
Conditions
peanut allergy
Beyond the preview
Go deeper on ACTRN12620001203943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001203943.